文献速递前列腺癌

保留Retzius间隙与标准机器人辅助根治性前列腺切除术治疗临床局限性前列腺癌的比较研究

Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-11-29

单术者队列研究比较保留Retzius间隙与标准机器人辅助根治性前列腺切除术,保留Retzius间隙组拔管后1周、1个月、2个月、3个月尿控恢复率均显著更高,6个月无显著差异;6个月勃起功能恢复率显著更高;两组围术期并发症率和切缘阳性率无显著差异。

要点

  • 保留Retzius间隙组拔管后1周尿控恢复率91.2% vs 对照组54.3%,差异显著。
  • 保留Retzius间隙组6个月勃起功能恢复率68.2% vs 对照组51.6%,差异显著。
  • 两组围术期并发症率9.8% vs 14.3%、切缘阳性率9.8% vs 8.6%,均无显著差异。

核心结论

  • 与标准机器人辅助根治性前列腺切除术相比,保留Retzius间隙入路显著改善术后即刻尿控,但未显著改善早期勃起功能恢复,且未增加围术期并发症率和切缘阳性率。

研究设计与样本

  • 单术者队列研究,纳入207例连续接受机器人辅助根治性前列腺切除术的患者,研究组102例接受保留Retzius间隙入路,对照组105例接受标准入路。

主要发现

  • 拔管后1周尿控恢复率研究组91.2% vs 对照组54.3%(p < 0.001)。
  • 拔管后1个月尿控恢复率研究组92.2% vs 对照组66.7%(p < 0.001)。
  • 拔管后2个月尿控恢复率研究组95.1% vs 对照组74.3%(p < 0.001)。
  • 拔管后3个月尿控恢复率研究组96.1% vs 对照组83.8%(p = 0.01)。
  • 拔管后6个月尿控恢复率研究组97% vs 对照组90.5%(p = 0.09),无显著差异。

关键数值与推荐

  • 拔管后6个月勃起功能恢复率研究组68.2% vs 对照组51.6%(p = 0.03)。
  • 围术期并发症率研究组9.8% vs 对照组14.3%(p = 0.28),无显著差异。
  • 切缘阳性率研究组9.8% vs 对照组8.6%(p = 0.75),无显著差异。
  • 多因素分析显示保留Retzius间隙入路是拔管后1周尿控恢复的独立预测因素,但不是6个月勃起功能恢复的独立预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retzius-sparing robot-assisted radical prostatectomy (RARP) is not yet universally accepted due to still limited functional data and some concerns on oncological safety compared to the standard one. We assessed perioperative, pathological and early functional outcomes in patients with clinically localised prostate cancer treated with Retzius-sparing versus standard RARP. METHODS: A single-surgeon cohort of 207 consecutive patients undergoing RARP was analysed. A later study group of 102 patients receiving the Retzius-sparing approach was compared with an earlier control group of 105 patients receiving the standard one. Urinary continence recovery 1 week after catheter removal was the primary study outcome. Urinary continence recovery 1, 2, 3 and 6 months after catheter removal, potency recovery 6 months postoperatively, rate of perioperative complications and positive surgical margins were secondary study outcomes. RESULTS: Patients in the study group reported significantly higher urinary continence recovery rates 1 week (91.2% vs. 54.3%, p < 0.001), 1 month (92.2% vs. 66.7%, p < 0.001), 2 months (95.1% vs. 74.3%, p < 0.001), 3 months (96.1% vs. 83.8%, p = 0.01), but not 6 months (97% vs 90.5%, p = 0.09) after catheter removal compared to controls. Potency recovery rates 6 months after catheter removal were significantly higher in the study than the control group (68.2% vs 51.6%, p = 0.03). On multivariable analyses, the Retzius-sparing approach was an independent predictor of 1-week urinary continence recovery, but not of 6-month potency recovery. There were significant differences neither in perioperative complication rate (9.8% in the study vs. 14.3% in the control group, p = 0.28) nor in positive surgical margin rate (9.8% in the study vs. 8.6% in the control group, p = 0.75). CONCLUSIONS: In a comparative study, we observed a significant improvement in immediate urinary continence, but not in early potency recovery, using the Retzius-sparing compared to the standard approach for RARP, with no increase in perioperative complication and positive surgical margin rate.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ficarra V, Rossanese M, Gilante M, et al. Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study. Prostate Cancer Prostatic Dis. 2022. PMID: 36443438. doi:10.1038/s41391-022-00625-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。